Altacor Ltd. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Altacor Ltd. ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Altacor Ltd. - Product Pipeline Review - 2012" provides data on the Altacor Ltd.'s
research and development focus. The report includes information on current developmental pipeline, complete with latest updates,
and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Altacor Ltd.'s corporate
website, SEC filings, investor presentations and featured press releases, both from Altacor Ltd. and industry-specific third party
sources, put together by Global Markets Direct's team.

Scope

- Altacor Ltd. - Brief Altacor Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Altacor Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Altacor Ltd. with complete description of the product's developmental
history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Altacor Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Altacor Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Altacor Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Altacor Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce
pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Altacor Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Altacor Ltd. and identify potential opportunities in those areas.

Table of Content

Altacor Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Altacor Ltd. Snapshot 5
Altacor Ltd. Overview 5
Key Information 5
Key Facts 5
Altacor Ltd. ' Research and Development Overview 6
Key Therapeutic Areas 6
Altacor Ltd. ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Altacor Ltd. ' Pipeline Products Glance 10
Altacor Ltd. ' Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Altacor Ltd. ' Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Altacor Ltd. ' Drug Profiles 13
ALT-005 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
ALT-020 14
R&D Progress 14
ALT-022 15
R&D Progress 15
ALT-088 16
R&D Progress 16
latanoprost 17
R&D Progress 17
PRX-00933 18
R&D Progress 18
tranilast 19



R&D Progress 19
Altacor Ltd. ' Pipeline Analysis 20
Altacor Ltd. ' Pipeline Products by Therapeutic Class 20
Altacor Ltd. ' Pipeline Products by Route of Administration 21
Altacor Ltd. ' Pipeline Products By Mechanism of Action 22
Altacor Ltd. ' Recent Pipeline Updates 23
Altacor Ltd. ' Locations And Subsidiaries 24
Head Office 24
Financial Deals Landscape 25
Altacor Ltd., Deals Summary 25
Altacor Ltd., Pharmaceuticals & Healthcare, Deal Details 26
Venture Financing 26
Altacor Secures $3 Million In Second Tranche Of Venture Financing 26
Altacor Raises $1.65 Million In First Tranche Of Series B Financing 28
Partnerships 30
Altacor Enters Into Licensing Agreement With OphthalmoPharma 30
Proximagen And Altacor Enter Into R&D Agreement For Treatment Of Glaucoma 31
PharmaNova Enters Into Co-Development Agreement With Altacor 33
Licensing Agreements 34
Altacor Enters Into Licensing Agreement With OphthalmoPharma For Latanoprost CD And Cyclosporin A Prodrug 34
Acquisition 36
NicOx Completes Acquisition Of 11.8% Stake In Altacor For $3 Million 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables

Altacor Ltd., Key Information 5
Altacor Ltd., Key Facts 5
Altacor Ltd. ' Pipeline by Indication, 2012 7
Altacor Ltd. ' Pipeline by Stage of Development, 2012 8
Altacor Ltd. ' Monotherapy Products in Pipeline, 2012 9
Altacor Ltd. ' Phase III, 2012 10
Altacor Ltd. ' Pre-Clinical, 2012 11
Altacor Ltd. ' Discovery, 2012 12
Altacor Ltd. ' Pipeline By Therapeutic Class, 2012 20
Altacor Ltd. ' Pipeline By Route of Administration, 2012 21
Altacor Ltd. ' Pipeline Products By Mechanism of Action, 2012 22
Altacor Ltd. ' Recent Pipeline Updates, 2012 23
Altacor Ltd., Deals Summary 25



Altacor Secures $3 Million In Second Tranche Of Venture Financing 26
Altacor Raises $1.65 Million In First Tranche Of Series B Financing 28
Altacor Enters Into Licensing Agreement With OphthalmoPharma 30
Proximagen And Altacor Enter Into R&D Agreement For Treatment Of Glaucoma 31
PharmaNova Enters Into Co-Development Agreement With Altacor 33
Altacor Enters Into Licensing Agreement With OphthalmoPharma For Latanoprost CD And Cyclosporin A Prodrug 34
NicOx Completes Acquisition Of 11.8% Stake In Altacor For $3 Million 36

List of Figures

Altacor Ltd. ' Pipeline by Indication, 2012 7
Altacor Ltd. ' Pipeline by Stage of Development, 2012 8
Altacor Ltd. ' Monotherapy Products in Pipeline, 2012 9
Altacor Ltd. ' Pipeline By Therapeutic Class, 2012 20


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Altacor Ltd. ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Altacor Ltd. ' Product Pipeline Review ' 2012